New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
February 9, 2010
07:17 EDTBIIB
theflyonthewall.com: Biogen Idec reports Q4 EPS $1.20 vs. consensus of $1.05
Reports Q4 revenue $1.1B vs. consensus $1.13B. :theflyonthewall.com



News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
There are 12 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 13, 2012
16:22 EDTBIIB
theflyonthewall.com: Biogen initiated with a Market Perform at Wells Fargo

Subscribe for More Information
:theflyonthewall.com

February 10, 2012
10:01 EDTBIIB
theflyonthewall.com: On The Fly: Analyst Initiation Summary

Subscribe for More Information
:theflyonthewall.com
09:27 EDTBIIB
theflyonthewall.com: Lazard Capital's biotech research team to hold a conference call

Subscribe for More Information
:theflyonthewall.com
06:36 EDTBIIB
theflyonthewall.com: Biogen initiated with an Overweight at Morgan Stanley

Subscribe for More Information
:theflyonthewall.com

February 9, 2012
16:27 EDTBIIB
theflyonthewall.com: Leerink's biotech and pharmaceuticals analysts hold a conference call
Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com

February 6, 2012
08:22 EDTBIIB
theflyonthewall.com: Biogen investigated for sales and promotional practices, WSJ reports

Subscribe for More Information
:theflyonthewall.com

January 31, 2012
11:21 EDTBIIB
theflyonthewall.com: Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Subscribe for More Information
:theflyonthewall.com
07:03 EDTBIIB
theflyonthewall.com: Biogen reports Q4 global in-market sales of TYSABRI $380M
Based upon data available to us through the TOUCH® prescribing program and other third-party sources, as of the end of December 2011, the company estimates that approximately 64,400 patients were on commercial and clinical TYSABRI therapy worldwide, and that cumulatively approximately 95,300 patients have ever been treated with TYSABRI in the post-marketing setting. :theflyonthewall.com
07:03 EDTBIIB
theflyonthewall.com: Biogen sees FY12 CapEx $230M-$250M

Subscribe for More Information
:theflyonthewall.com
07:03 EDTBIIB
theflyonthewall.com: Biogen sees FY12 adjusted EPS $6.10-$6.20 vs. consensus $6.32

Subscribe for More Information
:theflyonthewall.com
07:02 EDTBIIB
theflyonthewall.com: Biogen reports Q4 adjusted EPS $1.51 vs. consensus $1.49

Subscribe for More Information
:theflyonthewall.com

January 30, 2012
11:44 EDTBIIB
theflyonthewall.com: Leerink's biotech and pharmaceuticals analysts hold a conference call

Subscribe for More Information
:theflyonthewall.com